Patient must have a confirmed diagnosis of BPH via IPSS score and uroflowmetry. Perform a baseline urinalysis to rule out active urinary tract infection (UTI). Anticoagulant medication should be managed according to clinical guidelines. Obtain informed consent. Ensure the patient has a bladder of sufficient capacity for visualization. Administer prophylactic antibiotics per institutional protocol.
The patient remains under observation for 30-60 minutes post-procedure. A temporary transurethral catheter is often placed for 3-5 days to manage initial swelling. Instruct patient to increase fluid intake, avoid strenuous physical activity for 72 hours, and manage minor discomfort with over-the-counter analgesics. Follow up in 4-6 weeks to assess urinary symptoms and catheter removal status.
Comprehensive Clinical Guide: Rezum Water Vapor Therapy for BPH
1. Introduction and Clinical Overview
Benign Prostatic Hyperplasia (BPH) remains one of the most prevalent urological conditions affecting the aging male population. As the prostate gland enlarges, it exerts pressure on the urethra, leading to a constellation of symptoms collectively known as Lower Urinary Tract Symptoms (LUTS). While pharmacological interventions (alpha-blockers, 5-alpha-reductase inhibitors) are first-line treatments, many patients experience suboptimal efficacy or intolerable side effects.
Rezum Water Vapor Therapy represents a paradigm shift in minimally invasive surgical therapies (MIST). It is a convective thermal energy treatment that utilizes the stored thermal energy in water vapor to induce targeted cell necrosis in hyperplastic prostate tissue. Unlike traditional transurethral resection of the prostate (TURP), which involves physical tissue removal, Rezum is tissue-sparing, maintains sexual function, and can often be performed in an office or ambulatory surgical setting.
2. Technical Specifications and Mechanism of Action
The core principle of Rezum therapy is the use of convective heat transfer. By injecting controlled doses of sterile water vapor into the transition zone of the prostate, the procedure exploits the high heat capacity of steam.
The Physical Mechanism:
- Phase Transition: When the sterile water vapor is injected into the prostate tissue, it undergoes a phase transition from gas back to liquid.
- Energy Release: During this transition, the steam releases its latent heat energy directly into the surrounding tissue.
- Targeted Necrosis: The heat creates a zone of immediate cell death (coagulative necrosis). Because the steam is constrained by the anatomical structures of the prostate, it does not travel into non-target tissues, preserving the surrounding stroma.
- Natural Resorption: Over the weeks following the procedure, the body’s inflammatory and immune response naturally resorbs the necrotic tissue, effectively reducing the volume of the prostate obstruction and opening the urethral channel.
| Feature | Specification |
|---|---|
| Energy Source | Convective Thermal Energy (Water Vapor) |
| Temperature | Approximately 103°C (217°F) |
| Treatment Duration | ~9 seconds per injection |
| Invasive Level | Minimally Invasive / Transurethral |
| Anesthesia | Local, Sedation, or General |
3. Clinical Indications and Patient Selection
Rezum is indicated for men who meet specific anatomical and symptomatic criteria. Proper patient selection is the cornerstone of clinical success.
Ideal Candidates:
- Prostate Size: Typically indicated for prostates between 30g and 80g.
- Median Lobe: Rezum is unique in its ability to treat obstructive median lobes, which are often difficult to address with other MIST options.
- Symptom Severity: Patients with an IPSS (International Prostate Symptom Score) indicating moderate to severe LUTS.
- Medication Refractory: Patients who have failed or wish to discontinue daily BPH medications due to systemic side effects like orthostatic hypotension or sexual dysfunction.
Contraindications:
- Patients with a penile implant or an artificial urinary sphincter.
- Active urinary tract infection (UTI).
- History of prostate cancer (unless cleared by urologic oncology).
- Severe urethral stricture disease that prevents device passage.
4. Pre-Operative Preparation and Procedural Steps
Pre-Operative Protocol:
- Urinalysis: Ensure the patient is free of infection.
- Anticoagulation Management: While Rezum has a favorable bleeding profile, surgeons may suggest pausing blood thinners depending on the patient's cardiovascular risk.
- Anesthesia: The procedure can be performed under local anesthesia (prostatic block), IV sedation, or light general anesthesia depending on patient anxiety and anatomy.
The Procedural Steps:
- Cystoscopy: The surgeon performs a baseline cystoscopy to map the anatomy, identifying the bladder neck, the verumontanum, and the lateral lobes.
- Device Positioning: The Rezum delivery device is inserted transurethrally. The needle is deployed into the target lobe tissue.
- Vapor Injection: The surgeon delivers the steam. Each injection lasts exactly 9 seconds. The number of injections is determined by the size and shape of the prostate.
- Withdrawal: The needle is retracted, and the device is repositioned for the next injection site.
- Catheterization: A temporary Foley catheter is placed post-procedure to manage potential post-operative swelling and ensure drainage.
5. Post-Operative Recovery and Outcomes
Recovery Protocol:
- Catheter Management: Most patients require a catheter for 3 to 7 days to allow for the resolution of post-procedure edema.
- Hydration: Increased fluid intake is encouraged to flush the bladder.
- Activity: Patients are advised to avoid heavy lifting or strenuous exercise for approximately one week.
- Symptom Timeline: While some relief is felt quickly, the full therapeutic benefit is typically realized between 4 and 12 weeks as the necrotic tissue is resorbed.
Typical Outcomes:
- Symptom Relief: Significant improvement in IPSS scores, often by 50% or more.
- Sexual Function: Unlike TURP, Rezum has a near-zero incidence of retrograde ejaculation, making it the preferred choice for younger, sexually active men.
- Durability: Clinical data demonstrates sustained symptom relief at 5-year follow-up intervals.
6. Risks and Potential Complications
While Rezum is considered very safe, it is a medical procedure and carries inherent risks:
* Dysuria: Common in the first few weeks due to inflammation.
* Hematuria: Blood in the urine is expected but usually self-limiting.
* Urinary Retention: Temporary inability to void, necessitating the catheter.
* UTI: Risk of bladder infection post-procedure.
* Tissue Sloughing: Small amounts of necrotic tissue may pass in the urine as the prostate heals.
7. Alternative Treatments for BPH
It is essential to compare Rezum against other standard-of-care treatments:
| Treatment | Mechanism | Advantage | Disadvantage |
|---|---|---|---|
| TURP | Surgical Resection | Gold standard for large glands | Longer recovery, sexual side effects |
| UroLift | Mechanical Implants | Immediate opening of urethra | Does not treat median lobe well |
| Rezum | Water Vapor | Preserves sexual function | Requires temporary catheter |
| Medication | Pharmacological | Non-invasive | Daily compliance, systemic side effects |
8. Massive FAQ Section
1. Is Rezum considered a surgical procedure?
Yes, it is a minimally invasive surgical procedure performed in a clinical setting.
2. Does Rezum cause erectile dysfunction?
Clinical trials have shown no reported instances of de novo erectile dysfunction following Rezum therapy.
3. Will I need a catheter after the procedure?
Yes, most patients are sent home with a catheter for a few days to assist during the initial healing phase.
4. How long does the procedure take?
The actual treatment time is very short, often taking less than 10–15 minutes once the equipment is in position.
5. Can Rezum be used for very large prostates?
Rezum is generally limited to prostates under 80g. For significantly larger glands, open or robotic simple prostatectomy may be required.
6. Is the procedure covered by insurance?
Rezum is widely covered by Medicare and most major private insurance plans, though pre-authorization is recommended.
7. Does it treat prostate cancer?
No. Rezum is strictly for the treatment of Benign Prostatic Hyperplasia. It does not treat or cause prostate cancer.
8. When will I notice an improvement in my symptoms?
Most patients report significant improvement within 4 to 8 weeks post-procedure.
9. Can I drive home after the procedure?
If you receive IV sedation, you will need a driver. If the procedure is done under local anesthesia, you may be able to drive, but it is advised to have someone available.
10. What happens if Rezum doesn't work?
Rezum does not preclude future surgical interventions. If symptoms return after many years, patients can still undergo traditional procedures like TURP.
9. Conclusion for Clinicians and Patients
Rezum Water Vapor Therapy represents the intersection of clinical efficiency and patient-centric care. By prioritizing the preservation of anatomy and sexual function, it addresses the primary concerns of the modern BPH patient. However, success is predicated on rigorous patient selection and adherence to post-operative catheter protocols. As the landscape of urology continues to favor minimally invasive approaches, Rezum remains a cornerstone of modern BPH management.
Disclaimer: This guide is intended for informational purposes for healthcare professionals and patients. It does not replace professional medical advice, diagnosis, or treatment. Always consult with a board-certified urologist to determine if Rezum is the appropriate treatment for your specific clinical presentation.